How much does the Lao generic version of entrectinib cost?

Entrectinib is a new type of targeted therapy designed to treat certain types of cancer, particularly those harboring NTRK gene fusions or ROS1-positive mutations. As an oral drug, entrectinib inhibits the proliferation and survival of cancer cells by interfering with key signaling pathways required for tumor cell growth and spread.

Entrectinib is now on the market in China and has been successfully included in the medical insurance system. Domestic patients can purchase it directly. However, its price is quite expensive, with a cost of about 20,000 yuan. For detailed information on specific prices and medical insurance reimbursement, please consult the pharmacy staff of your local hospital.

It is worth mentioning that there are some relatively low-priced entrectinib generic drugs on the foreign market, especially Laotian generic drugs, which sell for about one to two thousand yuan, and after comparison, these generic drugs are basically consistent with the original drug in terms of drug ingredients.

NTRKgene fusions are rare but lethal cancer mutations that are common in certain solid tumors, such as infantile sarcomas and adult interstitial pneumonitis tumors (IMT). ROS1 mutations are mainly found in patients with non-small cell lung cancer (NSCLC). The unique feature of entrectinib is that it can effectively inhibit the growth and metastasis of tumors by inhibiting the activity of these mutant proteins, thereby prolonging patients' survival and improving their quality of life.

The development of entrectinib stems from the in-depth understanding of the molecular mechanisms of cancer and the continuous exploration of targeted therapies. It is an example of how by targeting tumor-specific biomarkers, this personalized approach can more effectively inhibit cancer progression while reducing damage to healthy tissue.

Clinical trials have shown that entrectinib has significant efficacy in the treatment of NTRK gene fusion-positive tumors and ROS1-positive non-small cell lung cancer. The study results show that entrectinib can cause partial or complete tumor shrinkage while prolonging patient survival, and can be used as a first-line treatment in some cases.